[go: up one dir, main page]

WO2015037009A8 - Protéines isolées capables de se lier à la plexine-a4, et procédés de production et d'utilisation - Google Patents

Protéines isolées capables de se lier à la plexine-a4, et procédés de production et d'utilisation Download PDF

Info

Publication number
WO2015037009A8
WO2015037009A8 PCT/IL2014/050827 IL2014050827W WO2015037009A8 WO 2015037009 A8 WO2015037009 A8 WO 2015037009A8 IL 2014050827 W IL2014050827 W IL 2014050827W WO 2015037009 A8 WO2015037009 A8 WO 2015037009A8
Authority
WO
WIPO (PCT)
Prior art keywords
methods
plexin
binding
producing
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2014/050827
Other languages
English (en)
Other versions
WO2015037009A1 (fr
Inventor
Yaron GRUPER
Revital ALOYA
Boaz Kigel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PLEXICURE Ltd
Original Assignee
PLEXICURE Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PLEXICURE Ltd filed Critical PLEXICURE Ltd
Publication of WO2015037009A1 publication Critical patent/WO2015037009A1/fr
Publication of WO2015037009A8 publication Critical patent/WO2015037009A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne des protéines isolées comprenant un domaine de reconnaissance d'antigène qui se lie spécifiquement à la plexine-A4 humaine. L'invention concerne également des procédés d'utilisation de ces protéines afin de traiter des troubles liés à l'angiogénèse, comme le cancer.
PCT/IL2014/050827 2013-09-16 2014-09-16 Protéines isolées capables de se lier à la plexine-a4, et procédés de production et d'utilisation Ceased WO2015037009A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361878125P 2013-09-16 2013-09-16
US61/878,125 2013-09-16

Publications (2)

Publication Number Publication Date
WO2015037009A1 WO2015037009A1 (fr) 2015-03-19
WO2015037009A8 true WO2015037009A8 (fr) 2015-05-14

Family

ID=51799129

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2014/050827 Ceased WO2015037009A1 (fr) 2013-09-16 2014-09-16 Protéines isolées capables de se lier à la plexine-a4, et procédés de production et d'utilisation

Country Status (1)

Country Link
WO (1) WO2015037009A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12472254B2 (en) * 2019-05-28 2025-11-18 Vib Vzw CD8+ T-cells lacking plexins and their application in cancer treatment
EP3976650A1 (fr) 2019-05-28 2022-04-06 Vib Vzw Traitement du cancer par ciblage des plexines dans le compartiment immunitaire
WO2022063957A1 (fr) 2020-09-24 2022-03-31 Vib Vzw Biomarqueur pour une thérapie antitumorale

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US6037137A (en) 1997-02-20 2000-03-14 Oncoimmunin, Inc. Fluorogenic peptides for the detection of protease activity
AU7073800A (en) 1999-08-25 2001-03-19 Regents Of The University Of California, The Novel plexins and uses thereof
WO2011066284A1 (fr) * 2009-11-25 2011-06-03 The University Of North Carolina At Chapel Hill Procédés et compositions destinés à traiter des troubles immunitaires
US20130330349A1 (en) 2011-02-23 2013-12-12 Rappaport Family Institute For Research In The Medical Sciences High affinity molecules capable of binding a type a plexin receptor and uses of same

Also Published As

Publication number Publication date
WO2015037009A1 (fr) 2015-03-19

Similar Documents

Publication Publication Date Title
WO2017031458A3 (fr) Conjugués anticorps-médicaments anti-dll3 et méthodes d'utilisation
AU2015347015A8 (en) Antibody drug conjugates
WO2015112886A3 (fr) Protéines de liaison et leurs procédés d'utilisation
WO2014160160A3 (fr) Conjugués anticorps-médicaments
WO2014163714A3 (fr) Conjugués médicament-anticorps
ZA201801083B (en) Single domain antibody for programmed death-ligand (pd-l1) and derived protein thereof
ZA201708265B (en) Tigit-binding agents and uses thereof
WO2015164392A8 (fr) Nouveaux anticorps antii-rnf43 et méthodes d'utilisation
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
WO2017136820A3 (fr) Technologie fit-immunoglobuline et ses utilisations
WO2015197598A3 (fr) Protéines multispécifiques de liaison à un antigène
MA39909A (fr) Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer
MX2016008667A (es) Inmunoglobulina con fab en tandem y usos de esta.
WO2015197823A3 (fr) Anticorps et fragments de liaison à l'antigène qui se lient spécifiquement à la protéine tau associée aux microtubules
PH12016502370A1 (en) Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
WO2016100985A3 (fr) Récepteurs antigéniques chimériques et leurs procédés d'utilisation
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
WO2017136659A3 (fr) Anticorps humanisés anti-cd3, conjugués et leurs utilisations
ZA201807920B (en) Anti¿gitr antibodies and uses thereof
WO2018031490A3 (fr) Protéines de liaison anti-ox40
WO2018069871A3 (fr) Protéines de liaison anti-kras
EP3529280A4 (fr) Anticorps dirigés contre les protéines mica et micb
WO2015054600A3 (fr) Composés interagissant avec le glycane et procédés d'utilisation
WO2015117088A3 (fr) Réactifs à base d'anticorps qui reconnaissent spécifiquement les formes de la protéine tdp-43 associées à une maladie neurodégénérative
WO2016020702A8 (fr) Anticorps anti-ténascine-c et utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14789899

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14789899

Country of ref document: EP

Kind code of ref document: A1